Holen Sie sich die Stockscreener-App
10.04
1.32%
0.21
Handel nachbörslich:
10.06
0.02
+0.20%
Schlusskurs vom Vortag:
$9.83
Offen:
$9.84
24-Stunden-Volumen:
809.06K
Relative Volume:
1.55
Marktkapitalisierung:
$526.15M
Einnahmen:
$9.68M
Nettoeinkommen (Verlust:
$-244.09M
KGV:
-2.2141
EPS:
-4.5346
Netto-Cashflow:
$-168.85M
1W Leistung:
+9.81%
1M Leistung:
-7.35%
6M Leistung:
-4.51%
1J Leistung:
+51.37%
1-Tages-Spanne:
$9.45
$10.07
1-Wochen-Bereich:
$9.04
$10.01
52-Wochen-Spanne:
$4.32
$11.80
Prothena Corp Plc Stock (PRTA) Company Profile
Firmenname
Prothena Corp Plc
Sektor
Branche
Telefon
011-353-1-236-2500
Adresse
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRTA
Prothena Corp Plc
|
10.05 | 514.63M | 9.68M | -244.09M | -168.85M | -4.5346 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prothena Corp Plc Stock (PRTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-05-27 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-27 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-01-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-04-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-06-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Oppenheimer | Outperform |
| 2021-05-26 | Eingeleitet | Citigroup | Buy |
| 2021-02-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-05-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-04-23 | Herabstufung | Jefferies | Buy → Hold |
| 2018-04-05 | Bestätigt | Barclays | Overweight |
| 2017-11-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2017-09-29 | Bestätigt | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2017-04-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-12-21 | Eingeleitet | SunTrust | Buy |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-08-04 | Bestätigt | Barclays | Overweight |
| 2016-05-13 | Eingeleitet | Barclays | Overweight |
| 2016-02-19 | Bestätigt | Wedbush | Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Prothena Corp Plc Aktie (PRTA) Neueste Nachrichten
Prothena (NASDAQ: PRTA) investors approve board, KPMG and executive pay - Stock Titan
Rubric Capital and David Rosen disclose 9.29% stake in Prothena (PRTA) - Stock Titan
Prothena Corp plc stock (IE00B91XRN20): Biotech investor focus amid pipeline updates - AD HOC NEWS
Number of shareholders of Prothena Corp. Plc – DUS:0PT - TradingView
PRTA Stock Price, Quote & Chart | PROTHENA CORP PLC (NASDAQ:PRTA) - ChartMill
William Scully reports 10.27% stake in PROTHENA (NASDAQ: PRTA) - Stock Titan
Prothena Corp. Down Over 9%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Prothena (PRTA) Heavy US$244 Million Annual Loss Tests Bullish Profitability Narratives - Sahm
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment - Yahoo Finance
Prothena (PRTA) Highlights Progress in Parkinson's Research and Collaborations - GuruFocus
Citizens raises Prothena stock price target on milestone payment By Investing.com - Investing.com UK
Prothena (PRTA) Revises 2026 Cash Outlook and Operating Expenses - GuruFocus
Prothena (NASDAQ:PRTA) Smashes Q1 Estimates on $50 Million Milestone Payment, Shares Steady - ChartMill
Prothena: Q1 Earnings Snapshot - marketscreener.com
Milestone revenue lifts Prothena (NASDAQ: PRTA) cash and pipeline - Stock Titan
Prothena (NASDAQ: PRTA) posts $32.7M Q1 profit and lifts 2026 cash outlook - Stock Titan
A $50M Novo milestone reshaped Prothena’s 2026 cash outlook - Stock Titan
Prothena Reports First Quarter 2026 Financial Results and Business Highlights - Yahoo Finance
Prothena to Report First Quarter 2026 Financial Results on May 7 - ChartMill
3 Growth Companies Insiders Are Eager To Hold - Sahm
Prothena (NASDAQ:PRTA) Shares Up 5.9%Time to Buy? - MarketBeat
FDA Fast Track granted to Phase 3 drug for ATTR-CM - Stock Titan
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy - The Joplin Globe
Prothena authorizes up to $100 million share repurchase plan - MSN
PRTA SEC FilingsProthena 10-K, 10-Q, 8-K Forms - Stock Titan
Price vs Value Analysis | Prothena Corporation posts 29.8% EPS beat with narrower loss - Cổng thông tin điện tử tỉnh Lào Cai
PRTA (Prothena Corporation plc Ordinary Shares) rises 3.61 percent after Q4 2025 EPS outpaces analyst consensus estimates.AI Powered Stock Picks - Xã Châu Thành
Liquidity Mapping Around (PRTA) Price Events - Stock Traders Daily
Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Prothena (NASDAQ:PRTA) Share Price Passes Above 200-Day Moving AverageTime to Sell? - MarketBeat
Prothena Corp plc stock (IE00B91XRN20): Why does its biotech pipeline matter more now for investors? - AD HOC NEWS
Prothena FY25 Earnings Review: Partnered Programs Advance Toward Milestones as Wholly-Owned Assets Pivot - AlphaStreet
Prothena Announces Leadership Team Updates - National Today
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN
Why (PRTA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Prothena Corp PLC (PRTA) Stock Earnings Transcripts - GuruFocus
Prothena (NASDAQ: PRTA) awards 100,000 stock options to Chief Strategy Officer - Stock Titan
Prothena (PRTA) Chief Strategy Officer reports 66,942 shares and option grants - Stock Titan
Prothena (PRTA) Strengthens Leadership Team with Key Promotions - GuruFocus
Prothena promotes Kingston, Isaacs to leadership roles - Investing.com
Prothena Corporation Announces Leadership Team Updates to Support Pipeline Development - geneonline.com
Prothena promotes Kingston, Isaacs to leadership roles By Investing.com - Investing.com India
Insider Sell: Will Prothena Corporation plc outperform tech stocksQuarterly Investment Review & Verified Swing Trading Watchlist - baoquankhu1.vn
PRTA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Published on: 2026-04-07 04:52:36 - baoquankhu1.vn
Is Prothena (PRTA) Stock Trending Down | Price at $10.05, Up 1.93%Real-time Trade Ideas - newser.com
Analyst Calls: How do insiders feel about Prothena Corporation plc2026 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
Gap Down: Can Prothena Corporation plc be recession proofWeekly Trend Report & AI Driven Price Predictions - baoquankhu1.vn
Prothena Corp plc Stock: Clinical Milestones and Strategic Focus in Biotechnology Drive Investor Int - AD HOC NEWS
PRTA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Finanzdaten der Prothena Corp Plc-Aktie (PRTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):